Carotenoid and Omega-3 Composition to Slow Alzheimer's Disease Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for neurodegenerative diseases like Alzheimer's disease are limited in effectiveness and cannot halt disease progression, and existing nutritional supplements show conflicting results in improving cognitive function or stabilizing the condition of subjects with cognitive impairment.
Innovation Solution
A composition comprising 10mg lutein, 2mg zeaxanthin, 10mg meso-zeaxanthin, and 1gm fish oil containing approximately 430mg DHA and 90mg EPA, administered orally, to treat or prevent Alzheimer's disease in human subjects with an MMSE score of 25 or less, with the potential to defer the onset of symptoms indefinitely or stabilize disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological treatments are used, then some symptomatic relief is achieved, but disease progression cannot be halted and effectiveness is strictly limited
Solution Approach 1:
The patent applies preliminary action by administering a combination of nutrients (omega-3 fatty acids, carotenoids, B vitamins) before significant cognitive decline occurs or at early stages of dementia. The study focuses on subjects with mild dementia (MMSE 21-26), aiming to prevent further progression through early nutritional intervention rather than treating advanced stages where damage is already done.
Solution Approach 2:
The patent uses a composite nutritional formulation combining multiple substances: omega-3 fatty acids (EPA and DHA), carotenoids (lutein, zeaxanthin, meso-zeaxanthin), and B vitamins (B1, B2, B3, B5, B6, B9, B12). This composite approach addresses the complexity of neurodegenerative disease by providing multiple nutrients that work synergistically to support brain health, reduce inflammation, and prevent oxidative stress.
2Reliability
If individual nutritional supplements (omega-3, carotenoids, vitamins) are administered, then some cognitive benefits are observed in certain studies, but other studies show conflicting results with no beneficial effect
Solution Approach 1:
The patent merges multiple individually studied nutrients into a single comprehensive formulation. Previous studies tested omega-3, carotenoids, and B vitamins separately with mixed results. This patent combines all three nutrient classes plus specific B vitamins into one formulation, creating a synergistic effect that addresses multiple pathways of neurodegeneration simultaneously.
Solution Approach 2:
The patent specifies precise dosages for each nutrient component: 1.2g EPA, 0.8g DHA, 10mg lutein, 4mg zeaxanthin, 2mg meso-zeaxanthin, and specific amounts of B vitamins. These optimized parameters were determined to achieve therapeutic levels in the brain while maintaining safety, addressing the variability in previous studies that used inconsistent dosing.
3Reliability
If Mediterranean Diet is followed, then better cognitive performance and reduced dementia risk are associated, but no clear evidence of the exact foodstuffs responsible is provided
Solution Approach 1:
The patent extracts the specific beneficial substances from the Mediterranean Diet pattern and tests them in isolation. The Mediterranean Diet is associated with cognitive benefits, but it's a complex dietary pattern making it difficult to identify which components are responsible. This patent isolates and tests specific nutrients (omega-3s from fish, carotenoids from vegetables, B vitamins from various sources) to determine their individual and combined effects.
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
A composition comprising at least one carotenoid selected from the group consisting of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid; for use in the prevention and/or treatment of dementia in a human subject.